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Background
The bioproduction of therapeutic proteins such as
monoclonal antibodies (mAb) continues to be a fast
growing sector of advanced manufacturing. The ever
increasing repertoire of therapeutic proteins coupled
with the emergence of biosimilars led to increasing glo-
bal demand for higher, faster, more cost-effective manu-
facturing process. Central to any good production
platform is the capacity of the production cell line. A
suitable production cell line exhibit physiological traits
such as high specific productivity (qp), rapid doubling
time, high peak cell density and efficient metabolism.
The emergence of a suitable production cell with all the
aforementioned traits is an extremely rare event, as it
requires all facets of cellular transcription, translation,
secretion and metabolic efficiency are individually opti-
mized and collectively synchronized into a system cap-
able of high level protein expression. One of the major
cellular bottlenecks thought to limit protein production
in mammalian cells lies in the cellular translation and
secretion capacity. The over-expression of complex
recombinant proteins such as mAbs driven by strong
viral promoters exert considerable burden in the Endo-
plasmic Reticulum (ER) and Golgi apparatus. The
increase in ER stress triggers the Unfolded Protein
Response (UPR) which can result in cell apoptosis and
possibly eliminating cells with high uptake of the Gene
of Interest (GOI). We adopted host cell engineering
approach using XBP1 spice ratio to expand cellular
translation and secretion capacity to increase qp and
improve the probability of isolating suitable high
producers.
Materials and methods
We screened a panel of mAb producing clonal cell lines
using qPCR to identify XBP1 mRNA splice ratio as a
suitable target to augment host cell translation and
secretion machinery. We then employed FACS to isolate
cell population with high ratio of spliced over unspliced
XBP1 in order to overcome the negative regulatory
effect of unspliced XBP1. We created a host cell line
with high XBP1 splice ratio, exhibiting increased expres-
sion of chaperones, secretary vesicle proteins and quality
assurance proteins without increasing UPR associated
apoptotic markers as identified using qPCR. This host
cell line was then used for in comparative mAb transi-
ent bioproduction studies with two different mAbs.
Transient studies were performed using PEI-mediated
transfection in industrial relevant chemically defined
medium and feeding regime.
Results
The XBP1 cell line demonstrated 7.5 fold increase in qp
over the control cell line and more than 4 fold increase
in final volumetric productivity (Figure 1). Moreover, we
also observed 3-fold increase in the percentage of high
producers with the XBP1 host cell line when we investi-
gated the producer cell population distributions post-
transfection. The XBP1 host cell derived mAb producing
cells also demonstrated competency in conventional
Stirred-tank bioreactor, showing promises of a commer-
cially viable production platform.
Conclusion
In conclusion, XBP1 splice ratio engineered host cell
have expanded translation and secretion capacity to alle-
viate the ER stress experienced from during mAb biopro-
duction. The augmented capacity allowed for multi-fold
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improvements in qp and volumetric productivity and
have the potential to increase the probability for isolating
high producers. The engineered host cell line showed
great promise to become a commercially suitable produc-
tion platform cell line to significantly reduce the time and
resources associated with cell line development.
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Figure 1 Comparative transient bioproduction of mAbs between the Control CHO-K1 derived cell line and Translation and Secretion
engineered XBP1 cell line.
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